Australian Regenerative Medicine Institute

Airway Response to a Bronchodilator in Healthy Parents of Infants With Bronchiolitis: Results

Airway Response to a Bronchodilator in Healthy Parents of Infants With Bronchiolitis: ResultsMain characteristics of the investigated subjects are reported in Table 1. There was no significant difference for anthropometric parameters nor for smoking habit between the two groups.
As stated in the Materials and Methods section, both groups had normal mean values of baseline lung function values: control subjects had slightly higher figures than parents of infants with bronchiolitis, but not significantly higher values.
Furthermore, no significant increase in FVC, FEVp and FEF25-75% values was observed after placebo administration in group 1. Conversely, after the inhalation of salbutamol, all parameters showed an increase, expressed as percentage of variation from the baseline value. In addition, the changes of FEVj and FEF25-75% values, but not of FVC, after salbutamol administration in the parents of infants with bronchiolitis were significantly different from the values measured after placebo inhalation (Table 2). On the contrary, in the control subjects, no significant increase was observed in the spirometric parameters after salbutamol administration with respect to baseline values (Table 2). canadian neighborhood pharmacy

Finally, the changes in FVC, FEVj, and FEF25-75% values in the parents of infants with bronchiolitis were significantly different from those of the control subjects after salbutamol administration (Table 2).
Indeed, using the criteria mentioned previously, 16 (24.2 percent) subjects of group 1 had a significant increase in at least one of the measurements (FVC, FEV., and FEF25-75% [Table 3]); conversely, no change resulted in the values for the control group.

Table 1 — Characteristics of Study Groups

Clinical Data Parents of Bronchiolitic Infants ControlSubjects
Males 33 33
Females 33 33
Age, yr 30.9 ±5.9 30.4 ±3.9
Height, cm 167.1 ±8.6 169.5 ±10.3
Smokers 20 19
Nonsmokers 46 47
Family history of atopy 4 5
Baseline lung funtion parameters
FVC (% predicted) 101.1 ± 14.8 107.6 ±15.2
FEV, (% predicted) 102.1 ± 13.5 105.8 ±11.6
FEF25-75% (% predicted) 108.8 ± 28.4 118.1 ±31.8

Table 2 —Mean Changes m Spirometric Indexes After Salbutamol or Placebo Inhalation (m Percent of Baseline)

Croup 1
Placebo Salbutamol p Value
FVCFEV,FEF25-75% 1.5 ± 6.3 1.0 ±5.1 -0.6 ±11.4 2.3    ± 4.95.4    ± 6.0 15.7 ±16.6 NS0.0010.001
Croup 1 Croup 2
Salbutamol p Value
FVCFEV,FEF25-75% 2.3    ± 4.95.4    ± 6.0 15.7 ±16.6 -0.9 ±5.5 1.0 ±5.3 6.8 ±10.2 0.010.0020.02

Table 3 — Number (Percent) of Subjects With a Significant Response to Salbutamol

Criteria Croup 1 Croup 2
FVC >15% 3 (4.5%) 0
FEV, >12% 14 (21.2%) 0
FEF25-75% >45% 5 (7.6%) 0
At least 1 index 16 (24.2%) 0

Category: Respiratory Symptoms

Tags: bronchodilator, bronchodilator response, hyperreactivity, hyperresponsiveness, infants bronchiolitis, lung function